Jameleddine, M.; Harzallah, N.; Grati, H.; Odabachian Jebali, M.C.; Chemli, J.; GarcÃa MartÃ, S.; Soto, N.; Pichon-Riviere, A.; Hamouda, C.
INEAS’s Cost-Effectiveness Analysis of Vemurafenib: Paving the Way for Value-Based Pricing in Tunisia. J. Mark. Access Health Policy 2024, 12, 294-305.
https://doi.org/10.3390/jmahp12040023
AMA Style
Jameleddine M, Harzallah N, Grati H, Odabachian Jebali MC, Chemli J, GarcÃa Martà S, Soto N, Pichon-Riviere A, Hamouda C.
INEAS’s Cost-Effectiveness Analysis of Vemurafenib: Paving the Way for Value-Based Pricing in Tunisia. Journal of Market Access & Health Policy. 2024; 12(4):294-305.
https://doi.org/10.3390/jmahp12040023
Chicago/Turabian Style
Jameleddine, Mouna, Nabil Harzallah, Hela Grati, Marie Christine Odabachian Jebali, Jaafar Chemli, Sebastián GarcÃa MartÃ, Natalie Soto, Andrés Pichon-Riviere, and Chokri Hamouda.
2024. "INEAS’s Cost-Effectiveness Analysis of Vemurafenib: Paving the Way for Value-Based Pricing in Tunisia" Journal of Market Access & Health Policy 12, no. 4: 294-305.
https://doi.org/10.3390/jmahp12040023
APA Style
Jameleddine, M., Harzallah, N., Grati, H., Odabachian Jebali, M. C., Chemli, J., GarcÃa MartÃ, S., Soto, N., Pichon-Riviere, A., & Hamouda, C.
(2024). INEAS’s Cost-Effectiveness Analysis of Vemurafenib: Paving the Way for Value-Based Pricing in Tunisia. Journal of Market Access & Health Policy, 12(4), 294-305.
https://doi.org/10.3390/jmahp12040023
